Marie Bosslett, Assistant Editor

This review of the latest dermatologic studies includes insights on a novel ultrasound technique for midface rejuvenation, sirolimus for reducing cSCC risk, dermatologists' role in social media dysmorphia, and more.

BioMendics is advancing TolaSure in the TAMES-02 trial for EBS, aiming for rapid market access and potential expansion to other keratinopathies.

Pediatric atopic dermatitis often leads to allergic comorbidities, increasing treatment needs and health care costs, according to a new Japanese study.

Quoin Pharmaceuticals seeks Breakthrough Medicine Designation for QRX003, aiming to provide the first treatment for Netherton Syndrome in Saudi Arabia.

Karen McGuire, PhD, discusses innovative TolaSure for treating epidermolysis bullosa simplex, focusing on disease modification rather than symptom management.

BOTOX Cosmetic's FDA approval for platysma bands revolutionizes non-surgical neck rejuvenation, offering dermatologists a new tool for effective patient care.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news on the commercial launch of cosibelimab-ipdl, dupilumab in pediatric AD, a phase 3 trial of lebrikizumab in nummular eczema, and more.

Renata Block, DMSc, MMS, PA-C, explores how AI could transform dermatology with insights from Dr. GPT on integration, equity, and the future of patient care.

Sun Pharma has launched cosibelimab-ipdl for advanced cutaneous squamous cell carcinoma, offering new hope for patients with limited treatment options.

Researchers explore CO₂ laser therapy's effectiveness for refractory HHD, revealing its potential to restore skin health and reduce inflammation.

Discover how auricular acupuncture could enhance facial aesthetics, offering non-invasive rejuvenation with rapid results and minimal downtime for wrinkle reduction.

Experts discuss real-world applications of JAK inhibitors for alopecia areata, emphasizing patient selection, psychosocial impacts, and personalized treatment strategies.

This review of the latest dermatologic studies includes insights on the "fear of overfilling," sexual adverse events from oral finasteride, post-laser, fibronectin-based skin care regimens, and more.

The RWEAL study uncovers real-world management of chronic hand eczema (CHE), highlighting treatment gaps and the need for standardized assessment in clinical practice.

Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.

Alpha Tau Medical advances Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC), offering a novel, localized treatment option with minimal toxicity.

New research confirms how skin tension line-oriented grafting enhances cosmetic outcomes in basal cell carcinoma surgery, improving aesthetics without compromising quality of life.

Adelle Walker explores the future of aesthetics as personalized, holistic approaches and regenerative treatments, particularly in younger patients, reshape trends in 2026.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news on phase 3 data of envudeucitinib for psoriasis, a combination treatment of ixekizumab and tirzepatide for PsA, a BLA pathway for sonelokimab in HS, and more.

Discover how trifarotene could enhance acne treatment in Malaysia, addressing both facial and truncal acne while improving hyperpigmentation and scarring.

A new study evaluates the quality and reliability of melasma posts on TikTok and Bilibili, highlighting gaps in treatment information and educational value.

Results from the TOGETHER-PsA trial reveal that combining ixekizumab and tirzepatide significantly improves outcomes for patients with psoriatic arthritis (PsA) and obesity.

CSU significantly impacts family quality of life, revealing the need for comprehensive care and support for both patients and their caregivers.

Jasper Therapeutics reveals promising briquilimab data, showcasing rapid disease control and safety in chronic spontaneous urticaria and chronic inducible urticaria.

Explore the effectiveness of herbal acne therapies vs social media trends, revealing both promising treatments and potential misinformation risks.

Johnson & Johnson's nipocalimab shows promise in reducing systemic lupus erythematosus activity, paving the way for a phase 3 development program.

Legacy Healthcare has advanced Cinainu into a phase 3 study for alopecia areata, offering hope for effective, safe treatment without immunosuppression.

This review of the latest dermatologic studies includes insights on dupilumab-associated rosacea, the prevalence of young adult acne, psoriasis patients with acute coronary syndrome, and more.